title: Type 1 cytokine response and treatment outcome of genital HPV lesions.
abstract: OBJECTIVE
  To determine the role of type 1 cytokines as predictors of response to treatment of genital HPV lesions with laser ablation with or without adjuvant systemic interferon alpha 2b (IFN-alpha).
  
  
  METHODS
  Measurement of serum interleukin 2 (IL-2), IL-2 soluble receptor alpha (sIL-2 alpha), interferon gamma, and human papilloma virus (HPV) DNA in patients undergoing treatment of genital HPV lesions with carbon dioxide laser and systemic IFN-alpha. A randomised, placebo controlled study of 92 cases with 6 months of follow up.
  
  
  RESULTS
  High IL-2/sIL-2 alpha was associated with 60% to 70% protection against recurrences both in the IFN-alpha and placebo groups (OR = 0.4, 90%, CI 0.1-2.5; OR = 0.3, 90% CI 0.0-1.8, respectively). Diagnostic phase serum IL-2 predicted favourable outcome (OR = 0.2, 90% CI 0.0-1.0) in women with high load of HPV DNA or HPV 16/18 DNA regardless of the adjuvant therapy.
  
  
  CONCLUSIONS
  Serum IL-2 determinations may identify women with good prognosis following laser ablation of genital HPV lesions.
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital, Helsinki, Finland.
authors.forename: G
authors.initials: G
authors.lastname: Stellato
authors.forename: P
authors.initials: P
authors.lastname: Nieminen
authors.forename: M
authors.initials: M
authors.lastname: Aho
authors.forename: T
authors.initials: T
authors.lastname: Lehtinen
authors.forename: M
authors.initials: M
authors.lastname: Lehtinen
authors.forename: J
authors.initials: J
authors.lastname: Paavonen
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D016207:Cytokines / Q000097:blood*; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D005831:Genital Diseases, Female / Q000097:blood / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000097:blood; D007376:Interleukin-2 / Q000097:blood; D017075:Laser Coagulation; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000097:blood / Q000188:drug therapy / Q000601:surgery*; D015375:Receptors, Interleukin-2 / Q000032:analysis; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D015415:Biomarkers; D016207:Cytokines; D004279:DNA, Viral; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D016899:Interferon-beta; D007371:Interferon-gamma